

Carcinosarcoma of the uterine cervix: A case report with immunohistochemical analysis.

ABSTRACT:

Carcinosarcoma of uterine cervix is a rare neoplasm. This report describes the histopathological and immunohistochemical profiles of a malignant cervical tumor with a mixed morphology of mesonephric carcinosarcoma and HPV dependent squamous cell carcinoma. A 51 year old female presented with the complain of bleeding per vagina since 2 weeks. MRI revealed a 36 x 50 x 45mm lesion involving cervix, lower uterine segment and vaginal fornices. The final histomorphology revealed a poorly differentiated tumor with mixed features of squamous cell carcinoma and mesonephric carcinosarcoma. Immunohistochemical analysis revealed expression of p40, p63, p16 and AR in squamous component and expression of GATA3, CD10 and Calretinin in mesonephric component. P16 positivity in squamous cell component indicated HPV associated carcinoma. The immunological findings support the metaplastic theory that carcinosarcoma may stem from the carcinomatous elements and then differentiate into sarcoma components. The

22 coexistence of carcinosarcoma and cervical squamous cell carcinoma in our
23 patient support this theory. Immunohistochemistry plays an important role for
24 diagnosis of such unusual mixed type of tumors.

25 **KEY WORDS:** mesonephric carcinosarcoma, HPV dependent squamous cell
26 carcinoma, immunohistochemistry.

UNDER PEER REVIEW IN IJAR

27 **INTRODUCTION:**

28 Carcinosarcoma is a biphasic malignant neoplasm composed of epithelial
29 and mesenchymal components. Primary cervical carcinosarcomas are much less
30 frequent than tumors arising in the uterine corpus or ovary. Some tumors are
31 associated with high-risk HPV infection (types 16 and 18).⁽¹⁾

32 **CASE REPORT:**

33 A 51 years old woman presented with the complain of bleeding per
34 vagina since 2 weeks. She was on medical treatment for hypertension. MRI
35 pelvis revealed a 36 x 51 x 45 mm lesion involving the cervix, lower uterine
36 segment and upper vaginal fornices. The cervical biopsy report indicated a
37 poorly differentiated malignant epithelioid to spindle cell tumor. The
38 immunohistochemical profile on cervical biopsy indicated mesonephric
39 carcinosarcoma. Both epithelioid and spindle cells express GATA-3 and CD 10
40 (Figure 3). The epithelioid cells express EMA, CK7, Calretinin and SF 1. The
41 tumor cells were negative for ER, PR, WT1, Cyclin D1 and Inhibin. After this,
42 the patient received 2 cycles of neoadjuvant systemic therapy (Paclitaxel and
43 carboplatin). MRI revealed a significant reduction in size of the cervical lesion.

44 Radical hysterectomy with bilateral salpingo-oophorectomy and and
45 bilateral pelvic lymphadenectomy was performed. The received specimen
46 consisted of uterus with bilateral adnexa and vaginal cuff. An irregular
47 infiltrative tumor was identified involving all four quadrants of the cervix and

48 extending upto lower uterine segment measuring 30 x 25 x 8 mm. Uterine
 49 corpus was normal on gross examination. Histopathological analysis of the
 50 infiltrating tumor revealed a mixed type of tumor consisting of Mesonephric
 51 carcinosarcoma and HPV- dependent Squamous cell carcinoma (Figure 1 & 2)
 52 associated with a
 53 high-grade squamous intraepithelial lesion.




Figure 1- Malignant mesenchymal component in mesonephric carcinosarcoma, H & E




Figure 2- Squamous cell component in mesonephric carcinosarcoma, H & E




Figure 3- Tumor cells express CD 10 in mesenchymal component




Figure 4- Tumor cells express p63 in squamous cell component




Figure 5- Tumor cells express p16 in squamous cell component

59 5) carcinosarcoma, H & E (40x). The mesenchymal component was negative for p40
 60 and p63 (moderate). The mesenchymal component was negative for p40
 61 and p63 (moderate). The mesenchymal component was negative for p40

62 lar in uterine invasion was not
 63 lymphovascular invasion was not
 64 ficat for tumor cells. The final
 65 adju (pTNM, AJCC 9th version).
 66 radiotherapy.

66
 67

68 Cervical carcinosarcoma is an extremely rare tumor, with only 128
69 documented cases in the literature.⁽²⁾ Cervical carcinosarcoma mainly occurs in
70 postmenopausal women, with a mean age at diagnosis of 64 years and a range
71 of 25 to 93 years.⁽²⁾ Patients usually present with vaginal bleeding as the initial
72 symptom, which leads to a diagnosis of a cervical mass.⁽³⁾ Our patient was 51-
73 years-old and presented with complain of vaginal bleeding. Most cervical
74 carcinosarcomas are detected in Stage IB, and at the time of diagnosis the
75 disease is confined to the cervix in most women, including our patient.^(2,4,5) The
76 histological features of carcinosarcoma are mixed comprising of epithelial and
77 mesenchymal component. Depending on the degree of differentiation based on
78 homologous and heterologous component further classified as homologous or
79 heterologous. Both adenocarcinoma and squamous cell carcinoma have been
80 observed as epithelial component of cervical carcinosarcomas.⁽⁶⁾ There is
81 increasing evidence that carcinosarcoma represents a mesenchymal metaplasia
82 of epithelial tumors.^(6,8) The coexistence of carcinosarcoma and squamous cell
83 carcinoma in our patient appears in agreement with this hypothesis.

84 Several etiologic factors related to the incidence of carcinosarcomas have
85 been reported, as radiation exposure to the pelvic area, previous chemotherapy
86 and infection with HPV, in particular type 16.^(6,7) Human papilloma virus
87 (HPV) infection can be an important cofactor in the carcinogenesis of cervical
88 carcinosarcoma.^(4,7,8) In this patient, squamous cell component is p16 positive

89 suggesting association with Human papilloma virus (HPV) infection. Grayson
90 et al. reported that HPV DNA was detected in all eight cases of the cervical
91 carcinosarcomas they reviewed.⁽⁸⁾

92

93 **CONCLUSION**

94 Carcinosarcoma of the uterine cervix is an extremely rare neoplasm,
95 mostly occurring in older age group. The coexistence of mesenchymal
96 component with p16 positive squamous cell component in our case supports the
97 evidence of metaplastic theory of histogenesis.

98

99 **REFERENCES**

- 100 (1) Yemelyanova A, Kong CS, Srinivasan R, Carcinosarcoma of the uterine
101 cervix, WHO classification of tumours, Female genital tumours, 5th edition, vol
102 4:p.391.
- 103 (2) Bansal S., Lewin S.N., Burke W.M., Deutsch I., Sun X., Herzog T.J.,
104 Wright J.D.: "Sarcoma of the cervix: natural history and outcomes". Gynecol.
105 Oncol., 2010, 118, 134. doi: 10.1016/j.ygyno.2010.04.021. Epub 2010 Jun 11.
- 106 (3) Sharma N., Sorosky J., Bender D., Fletcher M.S., Sood A.K.: "Malignant
107 mixed mullerian tumor (MMMT) of the cervix". Gynecol. Oncol., 2005, 97,
108 442.

- 109 (4) Clement P.B., Zubovits J.T., Young R.H. Scully R.E.: "Malignant mullerian
110 mixed tumors of the uterine cervix: a report of nine cases of a neoplasm with
111 morphology often different from its counterpart in the corpus". *Int. J. Gynecol.*
112 *Pathol.*, 1998, 17, 211.
- 113 (5) Laterza R., Seveso A., Zefiro F., Formenti G., Mellana L., Donadello N. et
114 al.: "Carcinosarcoma of the uterine cervix: case report and discussion".
115 *Gynecol. Oncol.*, 2007, 107, S98. Epub 2007 Aug 28.[4] Bansal S., Lewin S.N.,
116 Burke W.M., Deutsch I., Sun X., Herzog T.J., Wright J.D.: "Sarcoma of the
117 cervix: natural history and outcomes". *Gynecol. Oncol.*, 2010, 118, 134. doi:
118 10.1016/j.ygyno.2010.04.021. Epub 2010 Jun 11.
- 119 (6) Iida T, Yasuda M, Kajiwara H, Minematsu T, Osamura RY, Itoh J, et al.
120 Case of uterine cervical carcinosarcoma. *J Obstet Gynaecol Res* 2005;31:404–
121 8.
- 122 (7) Takeshima Y, Amatya VJ, Nakayori F, Nakano T, Iwaoki Y, Daitoku K, et al. Co-
123 existent carcinosarcoma and adenoid basal carcinoma of the uterine cervix and
124 correlation with human papilloma virus infection. *Int J Gynecol Pathol*
125 2002;21:186–90.
- 126 (8) Grayson W, Taylor L, Cooper K. Carcinosarcoma of the uterine cervix: a
127 report of eight cases with immunohistochemical analysis and evaluation of
128 human papillomavirus status. *Am J Surg Pathol* 2001;25:338–47.

UNDER PEER REVIEW IN IJAR